FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to novel compounds, namely, to N-substituted derivatives of piperidine of the formula (I): 
or their pharmaceutically acceptable salts, amides, esters wherein values R1, R, R3, m, X, n, W, Ar1 and Ar2 are disclosed in the invention claim. Also, invention relates to methods for inhibition of activity and methods for inhibition of activation of monoamine receptors. Methods involve contacting monoamine receptors or system comprising monoamine receptors with the effective amount of one or some compounds of the formula (I). Except for, invention relates to using compounds of the formula (I) in treatment of psychotic diseases.
EFFECT: valuable medicinal properties of compounds.
35 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SPIROAZACYCLIC COMPOUNDS, METHOD FOR INHIBITION IF ACTIVITY OR ACTIVATION OF SEROTONIN 5-НТ2А RECEPTOR, METHOD FOR TREATMENT OF MORBID STATE ASSOCIATED WITH SEROTONIN 5-НТ2А RECEPTOR AND THEIR USING | 2002 |
|
RU2315051C2 |
| AZACYCLIC COMPOUNDS TO BE USED IN TREATING SEROTONIN-MEDIATED DISEASES | 2001 |
|
RU2398765C1 |
| GLP-1 RECEPTOR AGONISTS AND USE THEREOF | 2017 |
|
RU2740135C1 |
| NMDA RECEPTOR MODULATORS AND THEIR APPLICATION | 2012 |
|
RU2621049C2 |
| GLP-1 RECEPTOR AGONISTS AND APPLICATION THEREOF | 2019 |
|
RU2765721C1 |
| CETP INHIBITORS | 2006 |
|
RU2513107C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | 2020 |
|
RU2820673C2 |
| FURIN INHIBITORS | 2019 |
|
RU2799824C2 |
| BENZIMIDAZOLE DERIVATIVES AS ROR-GAMMA MODULATORS | 2017 |
|
RU2760366C2 |
